Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01102270 · ClinicalTrials.gov registry record · Early Phase 1
The Effect of Eszopiclone on the Arousal Threshold in Sleep Apnea Syndrome
A Early Phase 1 study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 17
- Enrollment target
NCT01102270 is a Early Phase 1 study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 17 participants.
The verdict
NCT01102270, a Early Phase 1 study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
The purpose of this study is to find out whether taking eszopiclone (Lunesta) changes the breathing effort required to briefly wake people with obstructive sleep apnea from sleep (respiratory arousal threshold). We would like to see if taking eszopiclone can reduce the severity of obstructive sleep apnea in some people (those that have a low respiratory arousal threshold; i.e. wake up easily to respiratory stimuli).
Interventions
- DRUG Placebo
- DRUG Eszopiclone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2009-01 |
| Est. Completion | 2010-05 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01102270
The ClinicalTrials.gov registry entry for NCT01102270 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01102270 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01102270 about?
NCT01102270 is a clinical study titled "The Effect of Eszopiclone on the Arousal Threshold in Sleep Apnea Syndrome". The purpose of this study is to find out whether taking eszopiclone (Lunesta) changes the breathing effort required to briefly wake people with obstructive sleep apnea from sleep (respiratory arousal threshold). We would like to see if taking eszopiclone can reduce the severity of obstructive sleep ...
What is the current status of trial NCT01102270?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 17 participants. The study started on 2009-01. Estimated completion is 2010-05.
What interventions are being tested in trial NCT01102270?
The interventions under investigation include: Placebo (DRUG), Eszopiclone (DRUG).
Who is sponsoring clinical trial NCT01102270?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.